Cognitive impairment and Type 2 Diabetes Mellitus: Focus of SGLT2 Inhibitors Treatment.

[1]  W. Banks,et al.  The Blood–Brain Barrier, Oxidative Stress, and Insulin Resistance , 2021, Antioxidants.

[2]  Qingpeng Zhang,et al.  Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis , 2021, Frontiers in Cardiovascular Medicine.

[3]  G. Paolisso,et al.  SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies. , 2021, Pharmacological research.

[4]  J. Ali,et al.  Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice , 2021, Neurochemistry International.

[5]  V. Desantis,et al.  Diabetes and Alzheimer’s Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path? , 2021, Antioxidants.

[6]  D. James,et al.  The aetiology and molecular landscape of insulin resistance , 2021, Nature Reviews Molecular Cell Biology.

[7]  L. Stoeckel,et al.  Cognitive Function Among Older Adults with Diabetes and Prediabetes, NHANES 2011-2014. , 2021, Diabetes research and clinical practice.

[8]  L. Middleton,et al.  Glycemic Control, Diabetic Complications, and Risk of Dementia in Patients With Diabetes: Results From a Large U.K. Cohort Study , 2021, Diabetes Care.

[9]  V. Bild,et al.  Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer’s Disease and Diabetes , 2021, Biomedicines.

[10]  H. Ferris,et al.  The brain as an insulin-sensitive metabolic organ , 2021, Molecular metabolism.

[11]  H. Arab,et al.  Targeting ROS-Dependent AKT/GSK-3β/NF-κB and DJ-1/Nrf2 Pathways by Dapagliflozin Attenuates Neuronal Injury and Motor Dysfunction in Rotenone-Induced Parkinson's Disease Rat Model. , 2021, ACS chemical neuroscience.

[12]  S. Shoar,et al.  Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: a meta-analysis of small and large randomized controlled trials. , 2021, American journal of cardiovascular disease.

[13]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. , 2020, The New England journal of medicine.

[14]  M. Wiciński,et al.  Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury , 2020, Pharmaceuticals.

[15]  C. Zheng,et al.  Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection , 2020, International journal of molecular sciences.

[16]  H. Elewa,et al.  Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke. , 2020, Clinical therapeutics.

[17]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[18]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[19]  Gregory B. Lim.  Empagliflozin improves outcomes in HFrEF regardless of diabetic status , 2020, Nature Reviews Cardiology.

[20]  H. Koepsell.  Glucose transporters in brain in health and disease , 2020, Pflügers Archiv - European Journal of Physiology.

[21]  G. Shulman,et al.  Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks , 2020, The Journal of Biological Chemistry.

[22]  M. Hediger,et al.  Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application , 2020, Pflügers Archiv - European Journal of Physiology.

[23]  Changjiang Zhang,et al.  SGLT2i: beyond the glucose-lowering effect , 2020, Cardiovascular Diabetology.

[24]  G. Holman.  Structure, function and regulation of mammalian glucose transporters of the SLC2 family , 2020, Pflügers Archiv - European Journal of Physiology.

[25]  S. Verma,et al.  Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors , 2020, JACC. Basic to translational science.

[26]  A. Sinclair,et al.  Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. , 2020, The lancet. Diabetes & endocrinology.

[27]  R. Simó,et al.  Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis. , 2020, Metabolism: clinical and experimental.

[28]  G. Laverman,et al.  The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? , 2020, Kidney international.

[29]  M. Garcia-Alloza,et al.  Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes , 2020, Alzheimer's Research & Therapy.

[30]  M. Parihar,et al.  Cognitive impairments in type 2 diabetes, risk factors and preventive strategies , 2020, Journal of basic and clinical physiology and pharmacology.

[31]  Michael Wagner,et al.  The characterisation of subjective cognitive decline , 2020, The Lancet Neurology.

[32]  J. Rungby,et al.  Antidiabetic medication and risk of dementia in patients with type 2 diabetes. A nested case-control study. , 2019, European journal of endocrinology.

[33]  Dhiren Patel,et al.  The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit , 2019, Diabetes Therapy.

[34]  P. Bekinschtein,et al.  Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain , 2019, Front. Cell. Neurosci..

[35]  S. Fusco,et al.  Brain Insulin Resistance and Hippocampal Plasticity: Mechanisms and Biomarkers of Cognitive Decline , 2019, Front. Neurosci..

[36]  A. Tamrakar,et al.  SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018) , 2019, Expert opinion on therapeutic patents.

[37]  L. Heilbronn,et al.  Mitochondrial (Dys)function and Insulin Resistance: From Pathophysiological Molecular Mechanisms to the Impact of Diet , 2019, Front. Physiol..

[38]  M. Albert,et al.  The Association of Late-Life Diabetes Status and Hyperglycemia With Incident Mild Cognitive Impairment and Dementia: The ARIC Study , 2019, Diabetes Care.

[39]  T. Rieg,et al.  What does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition , 2019, Diabetes, obesity & metabolism.

[40]  G. Winterer,et al.  Associations of the metabolic syndrome and its components with cognitive impairment in older adults , 2019, BMC Geriatrics.

[41]  A. Pontecorvi,et al.  Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives , 2019, Cardiovascular Diabetology.

[42]  P. Fraser,et al.  The Link Between Tau and Insulin Signaling: Implications for Alzheimer’s Disease and Other Tauopathies , 2019, Front. Cell. Neurosci..

[43]  M. Maciejczyk,et al.  Insulin Resistance and Oxidative Stress in the Brain: What’s New? , 2019, International journal of molecular sciences.

[44]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[45]  Maria Casagrande,et al.  Executive Functions in Alzheimer Disease: A Systematic Review , 2019, Front. Aging Neurosci..

[46]  M. Khater,et al.  Role of Inflammatory Markers in Elderly Type 2 Diabetic Patients with Mild Cognitive Impairment. , 2019, Current diabetes reviews.

[47]  M. Perez-Pinzon,et al.  Brain SIRT1 Mediates Metabolic Homeostasis and Neuroprotection , 2018, Front. Endocrinol..

[48]  T. Dakic,et al.  Food For Thought: Short-Term Fasting Upregulates Glucose Transporters in Neurons and Endothelial Cells, But Not in Astrocytes , 2018, Neurochemical Research.

[49]  J. Martínez,et al.  Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study , 2018, Scientific Reports.

[50]  L. Jacob,et al.  Association Between the Use of Antihyperglycemic Drugs and Dementia Risk: A Case-Control Study. , 2018, Journal of Alzheimer's disease : JAD.

[51]  S. Perna,et al.  12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus , 2018, Clinical pharmacology : advances and applications.

[52]  A. Desmoulière,et al.  Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging , 2018, Aging and disease.

[53]  H. Koepsell,et al.  RS1 (Rsc1A1) deficiency limits cerebral SGLT1 expression and delays brain damage after experimental traumatic brain injury , 2018, Journal of neurochemistry.

[54]  M. Bohnert,et al.  Validation of sodium/glucose cotransporter proteins in human brain as a potential marker for temporal narrowing of the trauma formation , 2018, International Journal of Legal Medicine.

[55]  G. Biessels,et al.  Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications , 2018, Nature Reviews Endocrinology.

[56]  D. Yusuf,et al.  Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy , 2018, BMC Neurology.

[57]  N. Lago,et al.  Metabolic Syndrome and Neuroprotection , 2018, Front. Neurosci..

[58]  N. Katakami.  Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus , 2018, Journal of atherosclerosis and thrombosis.

[59]  S. L. la Fleur,et al.  Glucose-Sensing in the Reward System , 2017, Front. Neurosci..

[60]  N. Chattipakorn,et al.  SGLT2‐inhibitor and DPP‐4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD‐induced obese rats , 2017, Toxicology and applied pharmacology.

[61]  E. Ferrannini.  Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology. , 2017, Cell metabolism.

[62]  A. Bjourson,et al.  Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. , 2017, The Journal of endocrinology.

[63]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[64]  Blanka Klimova,et al.  Cognitive decline in normal aging and its prevention: a review on non-pharmacological lifestyle strategies , 2017, Clinical interventions in aging.

[65]  A. Chaudhury,et al.  Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management , 2017, Front. Endocrinol..

[66]  W. Cefalu,et al.  An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus , 2016, Current opinion in endocrinology, diabetes, and obesity.

[67]  T. Montine,et al.  Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach , 2016, Diabetes Spectrum.

[68]  V. Matthews,et al.  Is it time to think about the sodium glucose co‐transporter 2 sympathetically? , 2016, Nephrology.

[69]  E. Wright,et al.  Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice , 2016, The Journal of physiology.

[70]  S. Shakil,et al.  Forxiga (dapagliflozin): Plausible role in the treatment of diabetes‐associated neurological disorders , 2016, Biotechnology and applied biochemistry.

[71]  A. Paranjape,et al.  Glucose transporters: physiological and pathological roles , 2016, Biophysical Reviews.

[72]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[73]  R. Sandhir,et al.  Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal. , 2015, World journal of diabetes.

[74]  J. Rosenstock,et al.  Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors , 2015, Diabetes Care.

[75]  Lawrence A Leiter,et al.  Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes , 2015, Diabetologia.

[76]  M. Fine,et al.  Tight Glycemic Control and Use of Hypoglycemic Medications in Older Veterans With Type 2 Diabetes and Comorbid Dementia , 2015, Diabetes Care.

[77]  Yu Hasegawa,et al.  Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice , 2014, Cardiovascular Diabetology.

[78]  J. Schmeidler,et al.  The association of duration of type 2 diabetes with cognitive performance is modulated by long-term glycemic control. , 2014, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[79]  G. Paolisso,et al.  Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[80]  M. Monami,et al.  Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials , 2014, Diabetes, obesity & metabolism.

[81]  C. Hölscher.  The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[82]  S. Tokuyama,et al.  Neuroprotective effect through the cerebral sodium–glucose transporter on the development of ischemic damage in global ischemia , 2013, Brain Research.

[83]  E. Wright,et al.  Regional distribution of SGLT activity in rat brain in vivo. , 2013, American journal of physiology. Cell physiology.

[84]  P. Rabinovitch,et al.  mTOR is a key modulator of ageing and age-related disease , 2013, Nature.

[85]  M. Kuzuya,et al.  Cognitive dysfunction: An emerging concept of a new diabetic complication in the elderly , 2013, Geriatrics & gerontology international.

[86]  G. Paolisso,et al.  Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes , 2012, Diabetes Care.

[87]  G. Paolisso,et al.  Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks? , 2012, Advances in Therapy.

[88]  P. Moreira,et al.  Insulin in Central Nervous System: More than Just a Peripheral Hormone , 2012, Journal of aging research.

[89]  D. Loo,et al.  Biology of human sodium glucose transporters. , 2011, Physiological reviews.

[90]  G. Paolisso,et al.  Relationships Between Daily Acute Glucose Fluctuations and Cognitive Performance Among Aged Type 2 Diabetic Patients , 2010, Diabetes Care.

[91]  H. Tanila,et al.  Parallel increase in p70 kinase activation and tau phosphorylation (S262) with Aβ overproduction , 2008, FEBS letters.

[92]  M. Paccalin,et al.  mTOR/p70S6k signalling alteration by Aβ exposure as well as in APP‐PS1 transgenic models and in patients with Alzheimer's disease , 2005, Journal of neurochemistry.